BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim JC, Lee HC, Cho DH, Choi EY, Cho YK, Ha YJ, Choi PW, Roh SA, Kim SY, Kim YS. Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers. J Cancer Res Clin Oncol 2011;137:1571-80. [PMID: 21850381 DOI: 10.1007/s00432-011-1036-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Sánchez ML, Coveñas R. The Galaninergic System: A Target for Cancer Treatment. Cancers 2022;14:3755. [DOI: 10.3390/cancers14153755] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Kanazawa T, Misawa K, Shinmura K, Misawa Y, Kusaka G, Maruta M, Sasaki T, Watanabe Y, Carey TE. Promoter methylation of galanin receptors as epigenetic biomarkers for head and neck squamous cell carcinomas. Expert Rev Mol Diagn 2019;19:137-48. [PMID: 30640567 DOI: 10.1080/14737159.2019.1567334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Misawa K, Mochizuki D, Endo S, Mima M, Misawa Y, Imai A, Shinmura K, Kanazawa T, Carey TE, Mineta H. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis: METHYLATION PATTERNS OF THE GAL AND GALR1/2 GENES. Mol Carcinog 2017;56:1107-16. [DOI: 10.1002/mc.22577] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
4 Sipos F, Mũzes G, Patai AV, Fũri I, Péterfia B, Hollósi P, Molnár B, Tulassay Z. Genome-wide screening for understanding the role of DNA methylation in colorectal cancer. Epigenomics 2013;5:569-81. [PMID: 24059802 DOI: 10.2217/epi.13.52] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
5 Misawa K, Misawa Y, Kanazawa T, Mochizuki D, Imai A, Endo S, Carey TE, Mineta H. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Clin Exp Metastasis 2016;33:187-95. [PMID: 26572146 DOI: 10.1007/s10585-015-9768-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
6 Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci 2015;106:1722-9. [PMID: 26426205 DOI: 10.1111/cas.12827] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
7 Kanazawa T, Misawa K, Misawa Y, Uehara T, Fukushima H, Kusaka G, Maruta M, Carey TE. G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer? Toxins (Basel) 2015;7:2959-84. [PMID: 26251921 DOI: 10.3390/toxins7082959] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
8 Sanz-garcia E, Marino D, Elez E, Macarulla T, Capdevila J, Alsina M, Argilés G, Saurí T, Tabernero J. Elucidating the molecular aspects of colorectal cancer and their clinical importance. Colorectal Cancer 2015;4:175-83. [DOI: 10.2217/crc.15.21] [Reference Citation Analysis]
9 Lang R, Gundlach AL, Holmes FE, Hobson SA, Wynick D, Hökfelt T, Kofler B. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev 2015;67:118-75. [PMID: 25428932 DOI: 10.1124/pr.112.006536] [Cited by in Crossref: 215] [Cited by in F6Publishing: 224] [Article Influence: 30.7] [Reference Citation Analysis]
10 Ha YJ, Kim CW, Roh SA, Cho DH, Park JL, Kim SY, Kim JH, Choi EK, Kim YS, Kim JC. Epigenetic Regulation of KLHL34 Predictive of Pathologic Response to Preoperative Chemoradiation Therapy in Rectal Cancer Patients. International Journal of Radiation Oncology*Biology*Physics 2015;91:650-8. [DOI: 10.1016/j.ijrobp.2014.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
11 Misawa Y, Misawa K, Kanazawa T, Uehara T, Endo S, Mochizuki D, Yamatodani T, Carey TE, Mineta H. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer: Promoter Methylation of GALR2 in HNSCC. Cancer 2014;120:205-13. [DOI: 10.1002/cncr.28411] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
12 Polimanti R, Fuciarelli M, Destro-bisol G, Battaggia C. Functional diversity of the glutathione peroxidase gene family among human populations: implications for genetic predisposition to disease and drug response. Pharmacogenomics 2013;14:1037-45. [DOI: 10.2217/pgs.13.99] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
13 Jia Y, Guo M. Epigenetic changes in colorectal cancer. Chin J Cancer. 2013;32:21-30. [PMID: 22059907 DOI: 10.5732/cjc.011.10245] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]